World-Class Research Capabilities With Proven Results

CGI is dedicated to providing innovative diagnostic assays and products to the clinical oncology community in an effort to empower personalized disease management. CGI’s research focuses on the development of state-of-the-art applications for the detection of genomic abnormalities in cancer.

Initially, our goals were realized in the design and creation of an extensive portfolio of DNA-FISH (fluorescent in-situ hybridization) probes that could be utilized by both clinical and research laboratories for the detection of such abnormalities in hematopoietic and solid tumors.

Currently, diagnostic product development has expanded to include FISH-based detection assays and Microarrays. CGI’s FISH-based tests are panels of individual DNA-FISH probes designed to maximize the ability to detect, monitor and inform the treatment of specific cancers. Our microarrays are designed for the global interrogation of genomic abnormalities with clinical relevance to cancer. It is expected that new cancer biomarkers will also be discovered during these research efforts which CGI may choose to patent and develop.